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ABSTRACT 
 
TITLE : Comparison of efficacy of oral versus intramuscular vitamin B12 supplementation for 
treatment of vitamin B12 deficiency and  determination of cellular deficiency of vitamin B12 using 
serum homocysteine  as a surrogate marker in patients with  low normal serum vitamin B12 levels 
AIMS AND OBJECTIVES : To compare the efficacy of oral versus intramuscular vitamin B12 
supplementation for the treatment of vitamin B12 deficiency and to determine whether 
patients with low normal serum vitamin B12 levels have vitamin B12 deficiency at cellular 
level, using serum homocysteine as a surrogate marker 
MATERIALS AND METHOD :  Consecutive patients with vitamin B12 deficiency 
attending department of gastrointestinal sciences and satisfying the inclusion criteria during 
November 2009 to November 2010 were enrolled in  a  prospective randomized open label 
clinical trial to compare the efficacy of oral versus intramuscular treatment and followed up 
for 3 months. An intention to treat analysis was done using SPSS 16.0 software. Mann-
Whitney U test was used for continuous variables and Fisher’s exact test for categorical data. 
For the cross sectional study to determine the cellular deficiency of vitamin B12 using serum 
homocysteine levels as surrogate marker, consecutive patients with a serum vitamin B12 
<400pg/ml during the above study period were enrolled  and Spearman’s correlational studies 
were used. 
RESULTS : 60 patients (44male,16 female) were randomized in 1:1 ratio into oral and 
intramuscular treatment groups. The intention to treat analysis revealed no significant 
difference in the treatment response between the study groups(p=0.06). The intramuscular 
treatment was three times costlier than oral therapy. The most common cause of vitamin B12 
deficiency was pernicious anaemia. 74% of patients with low normal serum vitamin B12 
levels had hyperhomocysteinemia suggestive of cellular vitamin B12 deficiency. 
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CONCLUSIONS : Oral vitamin B12 supplementation is cheaper than and equally effective 
as intramuscular treatment for vitamin B12 deficiency. The most common etiology for vitamin 
B12 deficiency in a tertiary care hospital setting in India is pernicious anemia. A majority of 
patients with low normal serum vitamin B12 levels (200-400pg/ml) have 
hyperhomocysteinemia, suggestive of vitamin B12 deficiency at cellular level. Serum 
homocysteine is a useful ancillary test for the diagnosis of intracellular vitamin B12 
deficiency in patients with low normal serum vitamin B12 levels. 
KEY WORDS : vitamin B12, homocysteine, randomized trial, intracellular deficiency 
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INTRODUCTION 
 
  There is a high prevalence of vitamin B12 deficiency in rural as well as urban 
population in India (1) . The etiology and risk factors in our population has however, not been 
adequately   studied so far.  
The diagnosis of vitamin B12 deficiency is hampered by the lack of a gold standard 
diagnostic test. Studies have shown that serum vitamin B12 levels do not accurately reflect its 
deficiency at a cellular level, especially in the low normal range (2). The cellular deficiency 
of vitamin B12 is associated with elevated homocysteine levels, which is an important risk 
factor for cardiovascular morbidity (3). Hence it may be important to measure serum 
homocysteine, which is a cheap and sensitive surrogate marker of cellular vitamin B12 
deficiency, to identify a subgroup with intracellular vitamin B12 deficiency among individuals 
with low normal serum vitamin B12 levels, who may benefit from therapy. 
The current recommendation for treatment of vitamin B12 deficiency is intramuscular 
vitamin B12 supplementation for an indefinite period, which has serious implications on cost 
and convenience, in addition to injection related complications. Studies from western 
countries suggest that high dose oral vitamin B12 supplementation may be an equally 
effective alternative to intramuscular treatment (4).  However, the reports favouring oral 
vitamin B12 supplementation should be interpreted with caution in the Indian context, in view 
of morphological differences in the intestinal mucosa, high prevalence of intestinal parasitic 
infestations and uniqueness in the composition of intestinal microbiota reported in previous 
studies(5). So far, there have been no studies substantiating the efficacy of oral vitamin B12 
supplementation in Indian subjects. Hence there is an imminent need to evaluate the efficacy 
of cheaper and convenient option of oral therapy compared to the conventional intramuscular 
treatment for vitamin B12 deficiency. 
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It is also important to identify the treatable etiological factors responsible for vitamin 
B12 deficiency which may enable definitive therapy for a finite period instead of lifelong 
vitamin B12 supplementation. Though pernicious anaemia and food cobalamin malabsorption 
have been reported to be the common causes in other parts of the world, there could be other 
potentially treatable causes in the Indian context, on account of the differences in gut 
characteristics in our population, as discussed above. 
The present study was therefore conceived to address these important aspects of 
vitamin B12 deficiency such as comparison of efficacy of oral versus intramuscular treatment 
for vitamin B12 deficiency, elucidation of its causes in a tertiary care setting, and to evaluate 
whether the patients with low normal serum vitamin B12 levels have adequate intracellular 
function of vitamin B12 using serum homocysteine as a surrogate marker. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6 
 
AIMS AND OBJECTIVES 
 
 
(i) To compare the efficacy of oral versus intramuscular vitamin B12 supplementation for the 
treatment of vitamin B12 deficiency. 
 
(ii) To determine whether patients with low normal serum vitamin B12 levels have vitamin B12 
deficiency at cellular level, using serum homocysteine as a surrogate marker. 
 
(iii) To identify the causes of vitamin B12 deficiency in a tertiary care setting. 
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REVIEW OF LITERATURE 
 
HISTORY 
 
  The observation that pernicious anaemia responds to treatment with liver extracts in 
the early twentieth century heralded the search for the ‘anti pernicious anaemia factor’, which 
culminated in the isolation and crystallization of vitamin B12 a few decades later. The X-ray 
structure of vitamin B12 was subsequently elucidated in 1955 by Dorothy Hodgkin. It was 
only in 1972 that the total synthesis of vitamin B12 was elucidated after a decade long 
collective effort of over  a hundred scientists (6). 
STRUCTURE OF VITAMIN B12 
 
Vitamin B12 is a cobalt containing molecule with octahedral structure as shown in 
figure 1. It is the largest and the most complex of all vitamins. 
 
 
Figure 1 
Figure.1 Structure of vitamin B12
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DIETARY SOURCES AND BIOAVAILABILITY 
 
The major dietary sources of vitamin B12 are fish, shell fish, meat, milk and eggs. The 
bioavailability of the vitamin from animal sources is about 50% (except eggs which have a 
bioavailability of <9%). Though algae and blue green algae contain large amounts of vitamin 
B12, these compounds are inactive in mammals (‘pseudovitamin B12’) (7).  
The recommended minimum daily requirement for cyanacobalamin   is approximately  
2.4 micrograms (8). 
 
 VITAMIN B12 METABOLISM 
   
During gastric digestion, vitamin B12 in food is released and forms a stable complex 
with gastric R-binder or haptocorrin (a glycoprotein of unknown function present in 
secretions like saliva, gastric juice etc). On entering duodenum, this complex is digested 
releasing the vitamin which then binds to the intrinsic factor (a glycoprotein produced by 
parietal cells of stomach). The vitamin-intrinsic factor complex is resistant to proteolysis and 
travels down to the distal ileum where it binds to specific receptor called cubulin-amnionless 
in the mucosal brush border. The complex is then taken into the ileal enterocyte where the 
intrinsic factor is destroyed and the vitamin is transferred to transcobalamin II. The intrinsic 
factor mediated absorption of vitamin B12 in human beings becomes saturated  at 1.5 - 2.0 
micrograms per meal.  
The mechanism of release of the vitamin from intrinsic factor and its exit from the 
ileal enterocyte is not fully understood (9). About 10-30% of cobalamin in plasma is bound to 
transcobalamin (referred to as holotranscobalamin, which is the metabolically active form of 
vitamin B12) and the remaining is transported as a complex with haptocorrin. The 
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transcobalamin-vitamin B12 complex enters the target cells after attaching to the TC II 
receptor (10) 
In addition to the above mechanism, about 1% of orally administered vitamin B12 can 
be absorbed  by a passive mechanism throughout the intestine (this is the rationale for oral 
vitamin B12 supplementation)(4) 
The vitamin B12 taken up by the target cell is usually retained and utilized after 
conversion into its coenzyme forms –methyl and adenosylcobalamin(11). Within the cell, 
vitamin B12 is  crucial for three enzymatic processes  
• Methylcobalamin is required as a cofactor for the conversion of  homocysteine  to 
methionine. Therefore, vitamin B12 deficiency increases serum homocysteine levels.  
• Adenosylcobalamin is a cofactor for the conversion of methylmalonyl Co A to 
succinyl Co A.   
• Methylcobalamin is necessary for the conversion of  5-methyltetrahydrofolate to 
tetrahydrofolate  whioch is required for DNA and red blood cell production.  
 
The absorption of dietary vitamin B12, transportation to cells and the physiological 
role of vitamin B12 is outlined in figure 2 (12). 
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Figure 2 
 
Figure.2 vitamin B12 metabolism 
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VITAMIN B12 DEFICIENCY 
Definition  
Considerable variation exists in the definition of vitamin B12 deficiency owing to the 
lack of a gold standard test for the diagnosis. However, the widely accepted definitions are 
listed below (13): 
 
• Serum vitamin B12  levels <150 pmol/l (<200 pg/ml) along with clinical and/or  
 
hematological features of cobalamin deficiency. 
 
• Serum vitamin B12  levels <150 pmol/l  on two separate occasions. 
 
• Serum vitamin B12  levels <150 pmol/l and serum homocysteine levels >13  
 
mmol/l or methylmalonic acid levels >0.4 mmol/l  
 
( after excluding renal failure , folic acid and vitamin B6 deficiencies). 
 
• Serum holotranscobalamin levels <35 pmol/l. 
 
Epidemiology  
The estimated prevalence of vitamin B12 deficiency varies, depending on the 
diagnostic criteria used. The prevalence reported from various other countries are listed 
below (table 1). 
Refsum et al, in their study  on a selected urban population from Pune, India reported 
that about 75% had metabolic evidence consistent with vitamin B12 deficiency that can only 
partly be explained by a vegetarian diet(14).  In another study on rural as well as urban 
subjects, Yajnik and colleagues demonstrated that 67% of middle aged men from western 
India had  vitamin B12 deficiency(1). 
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Table 1. Prevalence of vitamin B12 deficiency 
 
Author   Year  Number of patients Cut off serum B12 
level (pmol/L) 
Prevalence 
(%) 
Blundell et al(15) 
(UK) 
1985 200 geriatric 
inpatients 
<122 10.0 
Hanger et al(16) 
(New Zealand) 
1991 204 geriatric 
subjects in 
community 
<114 7.3 
Pennypacker et al(17) 
(USA) 
1992 152 geriatric 
outpatients 
<221 and elevated 
homocysteine/MMA 
14.5 
Lindenbaum et al(18) 
(USA) 
1994 548 (Framingham 
cohort)  
<258 and elevated 
homocysteine/MMA 
11.3 
Matchar et al(19) 
(USA) 
1994 1599 inpatients and 
outpatients 
<133 and clinical 
signs, MMA 
5.2 
 
Table 1 
 
Natural history of vitamin B12 deficiency 
Table 2 illustrates the stages in the clinical progression of  vitamin B12 deficiency(20) 
 
Table 2. Stages of vitamin B12 deficiency 
Stage 1 Circulating serum B12 levels depleted  typically asymptomatic  
can remain so for several years  
Stage 2 Cellular stores of B12 are depleted  can remain asymptomatic.  
can also continue for several years.  
Stage 3 Evidence of biochemical deficiency                       
-increases in serum Homocysteine, MMA 
(methyl malonic acid) 
Vitamin B12 is required for the 
conversion of these compounds  
Stage 4 Clinical signs and symptoms apparent  manifestations is broad and the 
sequence varies markedly  
 
Table 2 
 14 
 
 
ETIOLOGY OF VITAMIN B12 DEFICIENCY 
 
Vitamin B12 deficiency may result from various inherited or acquired disorders as 
described below: 
I. Inherited causes of vitamin B12 deficiency(21) 
A. Disorders affecting absorption 
 
 
(i) Congenital pernicious anaemia- characterized by intrinsic factor 
deficiency. Gastric acid secretion and mucosal architecture are normal. 
The condition is rare and fewer than 100 cases only have been reported 
so far. It is treated by lifelong parenteral vitamin B12 supplementation. 
 
(ii) Imerslund-Gra¨sbeck syndrome- a rare, potentially fatal condition 
presenting in children of 3-10years, caused by mutations  affecting 
CUBN gene which encodes cubulin- the high affinity receptor for 
intrinsic factor-cobalamin complex in ileum- resulting in malabsorption 
of vitamin B12. More than 250 cases have been reported worldwide so 
far. Lifelong parenteral vitamin B12 supplementation is effective. 
 
 
B. Disorders of transport 
 
(i) Congenital transcobalamin deficiency- manifests in early infancy with 
macrocytic anemia, failure to thrive, and/or neurological features. Less 
than 50 cases have been reported in literature till date. The serum vitamin 
B12 levels are characteristically normal, as 80% of cobalamin in blood is 
bound to haptocorrin rather than transcobalamin. 
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C. Disorders of intracellular metabolism 
 
 
(i) The conversion of the vitamin to its coenzymes- methyl and adenosyl 
cobalamin- requires a series of biochemical modifications. Mutations in 
specific genes have been described for five of the eight complementation 
groups involved in this process 
 
 
II. Acquired causes of vitamin B12 deficiency 
 
 
A. Nutritional causes 
 
 
(i) Malnutrition 
 
 
(ii) Vegetarian diet-  a systematic comparison a group of US, Dutch, and 
British vegans with nonvegetarians from respective countries found that 
many of the vegans had significantly lower vitamin B12 concentrations 
compared to the nonvegetarians(22). Subsequently, Dhopeshwarkar and 
colleagues demonstrated that asymptomatic Indian lactovegetarians, who 
form  the majority of Indian population, had significantly lower serum 
vitamin B12 concentrations than nonvegetarians(23). This was confirmed 
by later studies from different geographic regions in India(24),  as well as 
the other parts of the world(25). 
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B. Defects in absorption  
 
(i) Food cobalamin malabsorption- defined as “a syndrome characterized by 
the inability of the body to release cobalamin from food or intestinal 
transport proteins, particularly in the presence of hypochlorhydria,where 
the absorption of ‘unbound’ cobalamin is normal(26)”. It  is arguably the 
most common cause of vitamin B12 deficiency in elderly patients(27) 
 
Diagnostic criteria(28): 
 
 
• Serum cobalamin level < 150 pmol/L 
 
• Result of standard Schilling test (with free cyanocobalamin 
marked with cobalt-58) is normal, or result of modified 
Schilling test (using radioactive cobalamin bound to food 
protein) is abnormal 
• No dietary cobalamin deficiency (intake > 2 μg/day) 
 
 
                                Associated conditions(13): 
 
 
-  Atrophic gastritis, chronic H pylori infection 
-  Small intestinal bacterial overgrowth 
-  Long-term ingestion of H2-receptor antagonists, proton pump 
    inhibitors or biguanides 
-  Chronic alcoholism 
-  Gastrectomy, gastric bypass surgery 
-  Pancreatic exocrine failure 
-  Advanced age  
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(ii) Lack of intrinsic factor or parietal cells 
 
 
• Pernicious anaemia(or Biermer’s disease) – a cell mediated 
autoimmune disease characterised by destruction of gastric 
fundic mucosa and presence of auto antibodies such as anti 
parietal cell antibody and anti intrinsic factor antibody(29). It 
accounts for 15-50% of cases of vitamin B12 deficiency. 
Associated conditions include autoimmune disorders like 
vitiligo, dysthyroidism, Addison’s disease, Sjögren’s syndrome 
as well as gastric neoplasms like adenocarcinomas, lymphomas 
and carcinoid tumours(30). 
• Atrophic gastritis 
• Gastrectomy  
 
(iii) Ileal disease 
 
• Crohns disease 
• Ileal resection 
 
(iv) Biologic competition 
 
• Bacterial overgrowth 
• Fish tapeworm infestation 
 
C. Defects in transport 
 
 
(i) Transcobalamin II deficiency 
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CLINICAL FEATURES (31)  
 
The majority of patients with vitamin B12 deficiency are asymptomatic. Less than 10% of 
patients have one or more of the classically described manifestations, which are listed below. 
• Hematologic 
o Megaloblastic anemia 
o Pancytopenia (leukopenia, thrombocytopenia) 
• Neurologic 
o  Paraesthesias 
o  Peripheral neuropathy 
o  demyelinating disease of dorsal columns and  corticospinal tract 
•  Psychiatric 
o Irritability, personality change 
o Mild memory impairment, dementia 
o Depression 
o Psychosis  
• Cardiovascular 
o  increased risk of myocardial ischaemia and cerebrovascular accidents 
 
Increasingly, the existence of “iceberg phenomenon” for vitamin B12 deficiency has 
been recognized and the entity of subclincal vitamin B12 deficiency has been defined as “ an 
asymptomatic state of vitamin B12 deficiency where metabolic deficiency is demonstrable” 
(32). Table 3 illustrates the features of subclinical cobalamin deficiency. 
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Table 3. Comparison of clinical and subclinical vitamin B12 deficiency 
 Clinical deficiency Subclinical deficiency 
Symptoms and  
signs  
 
 
Serum B12 levels 
 
 
 
Frequency  
 
 
 
Course 
 
Cause  
 
Treatment  
Present  
 
 
 
Low in 97% (<200pg/ml) 
 
 
 
<10% with serum B12 less 
than 200pg/ml 
 
 
Progressive 
 
Identifiable in most cases 
 
Mandatory  
Absent (may have 
electrophysiological changes) 
 
 
Usually lowl, but may be low 
normal 
 
 
70% with serum B12 <200pg/ml 
30%  serum  B12 200-400 range 
 
 
Unknown, may progress slowly 
 
Identifiable only in about 50% 
 
Advisable, dose unclear 
 
 
 
   
Table 3 
 
DIAGNOSIS 
 
There is no universally accepted gold standard diagnostic test for vitamin B12 deficiency. 
Therefore, the diagnosis is based on a constellation of clinical, haematological and 
biochemical parameters. Various serum biomarkers of vitamin B12 deficiency have been 
reported to be useful in this regard. 
Serum Biomarkers of  vitamin B12 deficiency(33) 
Though serum vitamin B12 estimation  is widely  used cost effectively as the  
diagnostic test of choice, it has only a limited sensitivity and specificity, especially in persons 
with vitamin B12 levels less than 400 pmol/L(low normal/ borderline range)(25).  
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In a study by Solomon et al,  the median intraindividual variation in measured serum 
vitamin B12 levels was 23 % and absolute differences >100 pmol/L on repeat testing was  
noted in 21 % patients (34). Stabler et al estimated that 5-10% of patients with serum vitamin 
B12 levels between 200 and 300 pg/mL and 0.1% to 1% with levels higher than 330pg/mL 
have a tissue deficiency of cobalamin(2).  
The serum levels of homocysteine and methyl malonic acid are elevated in vitamin 
B12 deficiency and have been shown to be reliable markers for tissue deficiency of 
cobalamin(35) 
  The various serum markers useful for the diagnosis of vitamin B12 deficiency are 
listed below  in table 4. 
 
 
Table.4 Serum biomarkers of vitamin B12 deficiency 
Marker Remarks 
Serum homocysteine High sensitivity, cheap, easily available 
Serum methyl malonic acid High sensitivity as well as specificity 
Requires mass spectrophotometry 
Available only at select centres 
Plasma holotranscobalamin Earliest marker to be elevated 
 
Table 4 
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Usefulness of serum homocysteine in the diagnosis of vitamin B12 deficiency 
 
 
Serum homocysteine estimation is a cheap, widely available and sensitive test 
(95.9%) for the detection of cellular deficiency of vitamin B12 and correlate well with methyl 
malonic acid levels (36). Studies have demonstrated a strong inverse correlation between 
serum levels of vitamin B12 and homocysteine(14),(37).  
However, elevation of serum homocysteine may also occur in smokers, alcohol abuse, 
renal failure and folate deficiency and these should be excluded before attributing it to 
vitamin B12 deficiency. Serum homocysteine has been reported as a useful adjunct for the 
determination of cellular vitamin B12 deficiency in patients with low normal/ borderline 
serum vitamin B12 levels(33). 
 
Functional tests of vitamin B12 absorption(33) 
 
(i) Schilling’s test : considered as gold standard functional test of cobalamin 
absorption. However need for radiolabelled cobalamin, cumbersome method and 
limited usefulness in renal failure, has made it impractical at present. 
 
(ii) Cobasorb test: a promising functional test  which measures  vitamin B12 
absorption by estimating the increase in holotranscobalamin with and without 
intrinsic factor administration. The test requires further evaluation before it can be 
incorporated into routine clinical use. 
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TREATMENT OF VITAMIN B12 DEFICIENCY 
 
Conventionally, vitamin B12 deficiency has been treated by parenteral (intramuscular 
route) supplementation with cyanacobalamin. However growing evidence suggests that oral 
vitamin B12 may be as good an option, regardless of the cause of vitamin B12 deficiency (38).  
The recommended standard treatment for vitamin B12 deficiency is described below. 
(i) Parenteral  route 
 
Intramuscular injection (over deltoid muscle)1000µg daily for one week ,followed 
by once a week for 8 weeks followed by a monthly maintenance dose of 1000µg, 
usually lifelong – especially in the case of pernicious anemia 
 
(ii) Oral route 
 
500µg daily for nutritional deficiency as well as food cobalamin malabsorption 
and 1000µg daily for pernicious anemia(28) 
 
Rationale for oral vitamin B12 supplementation 
 
• the main causes of cobalamin deficiency in the elderly are food-cobalamin 
malabsorption (50–70%)  and pernicious anaemia (20–30%)  
 
• between 1 and 5% of free cobalamin (or crystalline cobalamin) is absorbed along the 
entire intestine by passive diffusion(9) 
 
Evidence for oral vitamin B12 supplementation 
The various studies supporting oral vitamin B12 supplementation are listed below in table 5 
(39),(40) 
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Table 5. Studies on efficacy of oral vitamin B12 supplementation 
Study design Study 
population(n) 
Dose, duration 
of treatment 
Results  Reference  
Open 
prospective 
Food 
cobalamin 
malabsorption 
 
n=10 
650µg/day 
3 months 
Normalization of serum 
B12 -80% 
Clinical improvement-
20% 
Mean increase in Hb-
1.9g/dl 
Mean decrease in MCV- 
7.8fl 
No adverse events 
 
(41) 
Open 
prospective 
Non pernicious 
anemia 
 
n=20 
1000µg/day 
1 week 
Normalization of serum 
B12 -85% 
No adverse events 
(42) 
Open 
prospective 
Food 
cobalamin 
malabsorption 
 
n=30 
250-1000µg/day 
1 month 
Normalization of serum 
B12 -87% 
Mean increase in Hb-
0.6g/dl 
Mean decrease in MCV- 
3fl 
Dose effect≥500µg/day 
No adverse events 
 
 
(43) 
Open 
prospective 
Non pernicious 
anemia 
 
n=30 
125-1000µg/day 
1 week 
Normalization of serum 
B12 in all patients with at 
least one dose of 
≥250µg/day 
Dose effect≥500µg/day 
No adverse events 
 
 
(44) 
Open 
prospective 
Pernicious 
anemia 
 
n=10 
1000µg/day 
3 months 
Normalization of serum 
B12 -90% 
Clinical improvement-
30% 
Mean increase in Hb-
2.45g/dl 
Mean decrease in MCV- 
10.4fl 
No adverse events 
 
(45) 
 
Table 5 
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An evidence-based analysis by the Vitamin B12 Cochrane Group concluded that the 
efficacy of oral cobalamin therapy, with a dose between 1000 and 2000 micrograms  given 
initially daily and then weekly, is comparable to parenteral vitamin B12 supplementation, 
based on review of two randomized control trials described below (46) in table 6. 
 
Table 6. Clinical trials on oral versus intramuscular vitamin B12 supplementation 
 
Study  Year  Randomization 
method 
Number  Withdrawal Intent 
to treat 
Follow up 
Kuzminski(47) 
 
1998 Unclear 
Not blinded 
38 5 No  4 months 
Bolaman (48) 2003 Block 
randomization 
Not blinded 
70 10 No  3 months 
 
Table 6 
However, it must be borne in mind that the effect of oral cobalamin treatment in 
patients presenting with severe neurological deficits has not  been adequately studied till date. 
Therefore, parenteral cobalamin therapy remains recommended for these patients.(33) 
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MATERIALS AND METHOD 
 
              Study setting 
              Department of Gastrointestinal sciences, Christian medical college, Vellore 
              Study period 
              November 2009 to November 2010    
I. Comparison of efficacy of oral versus intramuscular vitamin B12 supplementation  
             
Study design 
Single centre prospective open label randomized intervention trial  
              Inclusion Criteria  
             All patients with documented vitamin B12 deficiency (serum vitamin B12 level <200pg/ml)  
who consent for the study  
Exclusion criteria 
1. Age <18years 
2. Pregnant individuals 
3. Renal failure  
4. Special cases where parenteral B12 supplementation is mandatory 
(eg: those patients with severe neurological deficits, intestinal failure etc) 
5. Already taking vitamin B12 supplements 
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Definitions 
 
(i) Vitamin B12 deficiency : serum vitamin B12 levels less than 200 pg/ml 
(ii) Treatment response : improvement in symptoms or signs along with either 
of the following – post treatment serum vitamin B12 > 200 pg/ml or post 
treatment serum homocysteine levels less than 13µM/L 
(iii) Pernicious anemia :  evidence of destruction of gastric fundic mucosa and 
presence of auto antibodies such as anti parietal cell antibody and/or anti 
intrinsic factor antibody 
(iv) Food cobalamin malabsorption : a syndrome characterized by the inability 
of the body to release cobalamin from food or intestinal transport proteins, 
particularly in the presence of hypochlorhydria,where the absorption of 
‘unbound’ cobalamin is normal 
(v) Vegetarian  : total abstinence from nonvegetarian diet at least during the 
last 3 years 
(vi) Significant Proton pump inhibitor(PPI)/Metformin/H2   receptor antagonists 
(H2RA) use : uninterrupted regular use for at least 6 months. 
(vii) Celiac sprue : Marsh III or above changes on duodenal biopsy along with 
IgA anti tissue transglutaminase (anti TTG) seropositivity 
(viii) Tropical sprue : intestinal mucosal disease characterized by malabsorption 
of two or more unrelated nutrient groups where other known causes of 
malabsorption have been excluded. 
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Sample size 
 
For  comparison of oral versus intramuscular treatment groups, 
Formula : number of patients, n= 2 Sp2 (z1-α/2 + z1-β/2) 
                         µd2 
where Sp2= s12+s22 
                         2  
Sp-standard deviation of mean of two groups 
S12- standard deviation of group 1 (intramuscular) 
S22- standard deviation of group 2 (oral) 
µd2- mean difference between samples 
α-significance level 
1-β – power of the study 
The values used for calculation were derived from a study comparing oral 
versus intramuscular vitamin B12 by Kuzminski and colleagues(47)             
[s1-165,s2-595, µd-400, α-5%, 1-β-80%] 
The calculated sample size, n = 19 in each arm of the study 
Outcome measures 
Primary outcome  
 – normalization of  serum vitamin B12 levels after treatment 
Secondary outcome  
–clinical:  improvement in symptoms and signs after  treatment 
                    - lab: change in Haemoglobin and MCV after treatment 
                    - compliance with either forms of therapy 
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              The study was approved by the ethics committee and the institutional review board of  
             Christian Medical College,  Vellore. 
Data was collected by the principal investigator using a standard proforma 
            (annexure1) after obtaining informed consent.                           
             All the patients found to have vitamin B12 deficiency underwent  a  
 
            comprehensive etiological evaluation and those who consented for the clinical trial 
 
            were randomly  assigned to oral or intramuscular treatment groups in a 1:1 ratio. The  
 
            randomization schedule  was computer generated with concealed allocation and was  
 
            prepared by someone uninvolved in  the study. As the primary outcome measures 
 
             were objective laboratory test reports, the use of placebo was not considered. 
 
The etiological evaluation included complete blood counts, pernicious anemia 
antibody screening, IgG anti TTG estimation, HIV serology, stool examination for 
parasites, endoscopic mucosal biopsy from fundus and antrum of the stomach, 
duodenum as well as ileum, abdominal imaging with either a contrast enhanced CT 
scan or a combination of ultrasound and barium meal follow through, as well as urine 
or blood xylose estimation to assess mucosal malabsorption. 
The study subjects in the oral group received 1000µg methylcobalamin tablets 
daily and those in the intramuscular group received 1000µg methylcobalamin over 
deltoid region daily for the first week of treatment followed by weekly injections for 8 
weeks and monthly injections subsequently till review. The patients were followed up 
during the hospital visit after completion of 3 months of treatment and clinical as well 
as laboratory parameters were reviewed. Compliance was assessed by patient’s 
account as well as pill / ampoule count and injection records where available. 
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II. Determination of intracellular vitamin B12 deficiency in patients with low 
normal serum vitamin B12 levels using serum homocysteine as a surrogate 
marker 
Study design 
Cross sectional observation study 
Inclusion criteria 
All patients with a serum vitamin B12 level less than 400pg/ml who consent for the 
study 
Exclusion criteria 
1. Age <18years 
2. Serum creatinine >1.4mg/dl 
3. Folic acid deficiency (serum folate <3ng/ml) 
4. Pregnancy 
5. Smoking or alcohol abuse 
6. Levodopa therapy 
7. Familial hyperhomocysteinemia 
 
Definitions  
(i) Low normal / Borderline vitamin B12 : serum vitamin B12 levels between 200 
to 400 pg/ml 
(ii) Hyperhomocysteinemia : serum total homocysteine levels more than 13 µM /L            
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Sample size 
 
For determination of sample size, values were derived from studies by Yao et al (49) 
and Delva et al (50). 
            Using nMaster software, estimated sample size,      n=40  
Where [sensitivity of serum homocysteine (new test)-96%, sensitivity of serum 
vitamin B12 (reference test)-80%,   α- 5%, 1-β -80%] 
The study was approved by the ethics committee and the institutional review board of  
Christian Medical College, Vellore  
Data was collected by the principal investigator using a standard proforma  
(annexure1) after obtaining informed consent.  
 
Measurement 
 
 Serum vitamin B12 was estimated by electrochemiluminescence immunoassay 
(ECLIA) method (normal>200pg/ml) and high performance liquid chromatography 
(HPLC) method was used for serum homocysteine estimation (normal<13µM)  
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STATISTICAL METHODS  
 
Data was analysed using SPSS software version 16.0. Continuous data is 
presented as mean with standard deviation and categorical data as proportions. 
Baseline characteristics were analyzed using Mann-Whitney U test for continuous 
variables and Fisher’s exact test for categorical data. For the comparison of oral and 
intramuscular treatment groups, an intention to treat analysis was performed, 
assuming a negative treatment response for the patients who did not complete the 
study. A per protocol analysis was also done. In addition to descriptive statistics, 
Spearman’s correlation was used to analyze the relationship between vitamin B12 and 
homocysteine.  
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RESULTS 
 
The study analysed multiple aspects of vitamin B12 deficiency such as 
(i) Comparison of efficacy of oral versus parenteral vitamin B12 supplementation 
(ii) Etiology of   vitamin B12 deficiency in tertiary care setting 
(iii) Correlation between serum vitamin B12 and serum homocysteine (a marker of 
intracellular vitamin B12 function) in patients with low normal serum vitamin B12 
levels 
The results are discussed below separately. 
 
I. Randomized trial of oral versus intramuscular vitamin B12 supplementation  
72 patients were found to have vitamin B12 deficiency, of which 60 subjects who consented 
for the therapeutic trial were randomized to oral and intramuscular treatment groups in a 1:1 
ratio. 27 patients in the intramuscular group and 22 patients in the oral group completed the 
study, as described in figure 3 below. 
 
 
 
 
 
 
  
Figure 3
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Baseline characteristics 
The baseline characteristics of both the study groups are illustrated below in table 7 
Table 7. Baseline characteristics of oral and intramuscular treatment groups 
Characteristics 
 
Intramuscular Oral P value 
Number of patients, n 
 
30 30 - 
Male gender (n,%) 
 
25 (83.3%) 19 (63.3%) 0.14 
Mean age (years) 
 
44.3±9.3 38.6±14.8 0.06 
Clinical features 
Diarrhea 
Anorexia 
Skin hyperpigmentation 
Neurological features 
Pallor  
No symptoms/signs 
 
 
19 
11 
2 
4 
6 
5 
 
11 
18 
4 
1 
7 
7 
 
0.07 
0.12 
0.67 
0.35 
0.76 
0.75 
Comorbidities 
Diabetes 
Hypertension 
  
 
2 
3 
 
4 
6 
 
0.67 
0.47 
Cause of B12 deficiency 
Pernicious anemia 
Atrophic gastritis 
Celiac sprue 
Tropical sprue/enteropathy 
Vegetarian diet 
Ileal resection 
Multiple causes 
No cause identified 
 
7 
6 
2 
1 
1 
1 
8 
4 
 
6 
6 
2 
4 
3 
1 
4 
4 
 
 
 
1.00 
1.00 
1.00 
0.35 
0.61 
1.00 
0.30 
1.00 
 
H.pylori infection 
 
 
20 
 
17 
 
0.60 
APCA 
Anti IF 
IgA anti TTG 
 
10 
5 
7 
10 
2 
6 
1.0 
0.42 
1.00 
Pre-treatment Hb (g/dl) 12.4±2.7 11.7±2.4 0.17 
Pre-treatment MCV (fl) 89.4±16.3 92.8±14.3 0.37 
Pre-treatment serum vitamin B12(pg/ml) 146.0±42.1 149.8±37.6 0.82 
 37 
 
 
There were 30 patients each in the oral and intramuscular treatment groups. The 
distribution of baseline characteristics such as age-sex distribution, clinical features, 
laboratory parameters, etiology as well as risk factors of both the study groups were similar 
(table 7). The most common cause of vitamin B12 deficiency was pernicious anemia in both 
the study groups. 
 
Treatment response 
All the 27 patients who completed intramuscular treatment and 20 out of  the 22 
patients who completed oral therapy, achieved normalization of serum vitamin B12 levels 
(table 8). 
Table 8. Post treatment serum vitamin B12 levels 
Post treatment serum 
Vitamin B12 (pg/ml) 
Intramuscular 
(n=27) 
Oral 
(n=22) 
<200 Nil 2 
200-300 2 2 
>300 25 18 
 
 
The intention to treat analysis, assuming lack of treatment response for the patients who did 
not complete the study showed no difference in treatment responses between the oral and 
intramuscular treatment groups (p=0.06).  
Similar finding was observed in  per protocol analysis as well (p=0.2). 
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The post treatment parameters of both the study groups are listed below (table 9). 
Table 9. Comparison of post treatment parameters 
Test Intramuscular Oral p value 
Serum vitamin B12 (pg/ml) 1128.3±543.0 488.4±173.1 <0.01 
Hb (g/dl) 13.4±2.2 12.8±2.0 0.45 
MCV(fl) 86.5±8.1 87.3±8.1 >0.05 
 
There was no significant difference in the increase in haemoglobin (Hb) levels or 
decrease in mean corpuscular volume (MCV) between the oral and intramuscular treatment 
groups. The increase in serum vitamin B12 levels after treatment was higher in patients who 
received intramuscular treatment, compared to those who were on oral therapy (mean change 
982.3 vs 338.6 pg/ml respectively, p<0.01). 
Serum homocysteine levels before and after treatment were available for 3 patients in 
intramuscular group and 7 patients in the oral treatment group. The post treatment levels were 
much lower than the pre-treatment values in all these patients. 
Among patients who received oral treatment, there was no difference in treatment 
response between patients who had pernicious anaemia compared to those who had vitamin 
B12 deficiency due to other causes (p=0.37) 
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Compliance  
All the patients (from oral as well as intramuscular treatment groups) who completed the 
study reported ≥80% compliance to treatment. 
 
Cost analysis (for 3 months of treatment) 
 Cost of oral vitamin B12 supplementation 
= cost of 1000µg methylcobalamin(daily dose) x duration of treatment 
= Rs 12.50 x 90 
= Rs 1125.00 
 Cost of intramuscular vitamin B12 supplementation 
= (cost of 1000µg methylcobalamin + disposable syringe and needle + injection charges)  
    x number of doses for 3 months 
= Rs (190.8 + 5.0 + 30) x 16 
= Rs 3612.80 
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II. Etiology of vitamin B12 deficiency  
Complete etiological evaluation was done for  the 72 patients detected to have vitamin B12 
deficiency who were screened for the randomized trial. The various causes identified are 
listed below (table 10) 
Table 10. Causes of vitamin B12 deficiency 
Cause Number of 
patients(n=72) 
% 
Pernicious anaemia 17 24 
Atrophic gastritis-H pylori related 
                               Non H pylori related 
13 
2 
18 
2 
Tropical sprue/enteropathy 5 7 
Celiac sprue 4 6 
Vegetarian diet 4 6 
Ileal resection 2 2 
Multiple causes* 17 24 
No cause identified 8 11 
*included those causes listed above as well as other causes such as PPI/H2RA/Metformin  use, 
pancreatic exocrine insufficiency, persistent giardiasis with malabsorption etc 
 
The most common cause of vitamin B12 deficiency in the study population was pernicious 
anaemia, followed by atrophic gastritis (involving fundus of stomach). More than one cause 
existed   in 24% patients, which included pancreatic exocrine insufficiency, chronic use  of 
metformin/proton pump inhibitor/H2 receptor antagonists and parasitic infestation such as 
refractory giardiasis. No cause was identified for 8 out of 72 study subjects (11%). 
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III. Correlation between serum vitamin B12 and homocysteine 
 
For the analysis of correlation between serum vitamin B12 and homocysteine levels, 
97 patients (61 male, 37 female) with serum vitamin B12 levels less than 400pg/ml were 
enrolled. 
47 patients had  serum vitamin B12 levels less than 200pg/ml and 50 had serum vitamin B12 in    
200-400pg/ml range. 
 
Characteristics of the study population 
 
Table 11 illustrates the distribution of baseline characteristics of the study population (n=97). 
 
Table 11. Patient characteristics 
 
 
Male gender 
Age (years) 
Hb (g/dl) 
MCV(fl) 
Serum homocysteine (µM) 
Serum Vitamin B12(pg/ml) 
 
 
61 (63%) 
40.9±13.0 
12.3±2.3 
88.1±12.7 
26.8±17.5 
203.9±70.0 
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Correlation between vitamin B12 and homocysteine 
The correlation between serum vitamin B12 (0-400pg/ml range) and homocysteine is 
demonstrated below (figure 4) 
 
Figure 4. Correlation between serum vitamin B12 and serum homocysteine
 
There was a significant inverse correlation between serum vitamin B12 and homocysteine 
levels (Spearman correlation coefficient, r = -0.47, p<0.01) 
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On further analysis using a Loess curve, it was found that though there was a strong 
inverse correlation between serum vitamin B12 and serum homocysteine levels in patients 
with vitamin B12 deficiency, ie serum vitamin B12 <200 pg/ml (Spearman correlation 
coefficient, r = -0.44, p<0.01), the same was not true for the patients with low normal serum 
vitamin B12 levels, ie 200-400 pg/ml ((Spearman correlation coefficient, r = -0.22, p=0.11). 
This is demonstrated in the figure below (figure 5) 
 
Figure 5. Loess curve showing difference in correlation of serum vitamin B12 
<200pg/ml and 200-400pg/ml with serum homocysteine 
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Cellular deficiency of vitamin B12 in patients with low normal serum vitamin B12  
 
50 patients with a serum vitamin B12 level in the low normal range of 200-400pg/ml 
were analysed to find out whether they have a cellular deficiency of vitamin B12, using serum 
homocysteine as a surrogate marker. 
 
37 patients (74%) had elevated serum homocysteine levels suggestive of vitamin B12 
deficiency at cellular level. 
 
Risk factors for vitamin B12 deficiency (figure 6) such as long term metformin or 
proton pump inhibitor use, vegetarian diet etc were more common in patients who had 
hyperhomocysteinemia 
 
The clinical features suggestive of cobalamin deficiency (figure 7) were more 
common in patients with elevated homocysteine levels, consistent with inadequate 
intracellular function of vitamin B12 
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Figure 6 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 
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Using receiver operating characteristic (ROC) curve method, the currently recommended 
lower limit of normal serum vitamin B12 level ( 200 pg/ml) was found to have a sensitivity of 
only 81.2% for the diagnosis of intracellular vitamin B12 deficiency, using serum 
homocysteine levels as a surrogate marker. 
 
Figure 7. ROC curve using serum vitamin B12 and serum homocysteine levels
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DISCUSSION 
 
Studies on rural and urban population in western India have demonstrated a higher 
prevalence of  vitamin B12 deficiency compared to western countries and established its  
association  with hyperhomocysteinemia, which is a known cardiovascular risk factor (14)(1). 
However, not much is known about the causes of vitamin B12 deficiency in the Indian setting.  
Eventhough the vast majority of patients with  vitamin B12 deficiency are in  
subclinical stage and do not have classically described clinical manifestations, at least some 
of them  may be at an increased risk for developing serious clinical consequences if not 
detected and treated early. The treatment is safe and remarkably efficacious if initiated before 
permanent clinical sequelae occur. 
The detection of vitamin B12 deficiency is hampered by the poor ability of serum 
vitamin B12 estimation to reflect cellular deficiency of the vitamin in the low 
normal/borderline range (2)(25). The above suggests that there is an imminent need for 
developing a reliable technique for the detection of cellular deficiency of vitamin B12 . Given 
the high prevalence of vitamin B12 in our population, it is also important to evolve a cost 
effective strategy for its treatment. 
The present study determined the etiology of vitamin B12 deficiency in a tertiary care 
setting, compared the efficacy of oral versus parenteral vitamin B12 supplementation in 
patients with vitamin B12 deficiency, examined the correlation of serum levels of vitamin B12 
and homocysteine, and looked into the presence of cellular deficiency of vitamin B12 in 
patients with low normal serum vitamin B12 using serum homocysteine as the surrogate 
marker. To our knowledge this is the first study of its kind from the Indian subcontinent. 
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The data available from previous small studies suggest equal efficacy of high dose 
oral and parenteral modes of vitamin B12 supplementation (table 5, 6). However, data from 
tropical countries are lacking, and given the difference in gut characteristics in terms of 
intestinal mucosal morphology, composition of intestinal microbiota and a high prevalence of 
parasitic infestations, the extrapolation of the western data to our population is questionable. 
The present study confirms that oral vitamin B12 supplementation is as effective as 
intramuscular treatment in the normalization of serum vitamin B12 levels in patients with 
vitamin B12 deficiency. The improvements in other clinical and laboratory parameters (such 
as haemoglobin, mean corpuscular volume and serum homocysteine ) were also found to be 
similar between the two study groups. The patients showed good compliance to both forms of 
treatment. However the intramuscular vitamin B12 supplementation was three times more 
expensive compared to the oral therapy and did not seem to confer any significant advantages 
over oral vitamin B12 supplementation. 
The study also revealed that the response to oral treatment did not differ between 
patients with vitamin B12 deficiency due to pernicious anaemia and those with vitamin B12 
deficiency due to other causes. This finding suggests that oral vitamin B12 supplementation 
may be effective regardless of the cause of vitamin B12 deficiency. 
The majority of patients (74%) with borderline serum vitamin B12 levels (200-
400pg/ml) was found have hyperhomocysteinemia, suggestive of vitamin B12 deficiency at 
cellular level. The finding substantiates the usefulness of serum homocysteine as an ancillary 
test to guide treatment in patients with low normal serum vitamin B12 levels. 
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We found that a strong inverse correlation exists between serum vitamin B12  and 
serum homocysteine levels in patients with vitamin B12 deficiency, consistent with the 
previous studies by Fakhrzadeh et al and Refsum et al(14)(37). However, a similar 
correlation was not found in patients with low normal/borderline serum vitamin B12 levels. 
This may be partially explained by the poor reliability and high intraindividual variation of 
serum vitamin B12 estimation in low normal/borderline range (200-400pg/ml) (34).  
Preliminary studies have reported that plasma holotranscobalamin estimation may be a better 
indicator of vitamin B12 deficiency as it measures the metabolically active form of vitamin  
B12  rather than the total serum vitamin B12 levels(51). Further studies are needed to identify a 
cheap, widely available, highly sensitive and specific serum biomarker which accurately 
reflects the intracellular deficiency of vitamin B12. 
Using the ROC curve method, it was found that the current serum vitamin B12 level 
cut off of 200pg/ml fails to identify about 19% of patients with intracellular vitamin B12 
deficiency. Large correlational studies between serum vitamin B12 and the novel serum 
biomarkers of vitamin B12 deficiency are needed to redefine the best cut off value for the 
lower limit of normal serum vitamin B12 levels. 
The study  also throws light into the etiology of vitamin B12 deficiency in a tertiary 
care setting in India. Pernicious anemia, followed by atrophic gastritis involving gastric  
fundus were the most common causes. This finding is similar to the data previously reported  
from the western countries. Importantly, a number of treatable causes like celiac sprue, 
tropical sprue etc were identified.  The cause of vitamin B12 deficiency could be successfully 
elucidated in 89% of the patients with the combination of endoscopic and laboratory 
investigations used in the study, even without the use of Schilling’s test.  
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There were a few limitations for our study such as small size of study population and  
short follow up period. The correlation between serum vitamin B12 and serum homocysteine 
at  serum vitamin B12 levels >400pg/ml has not been addressed. Concurrent estimation of 
methyl malonic acid would have allowed a more specific diagnosis of cellular deficiency of 
vitamin B12.  
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CONCLUSIONS 
 
 
 
 Oral vitamin B12 supplementation is cheaper and equally effective as intramuscular 
treatment for vitamin B12 deficiency. 
 
 A majority of patients with borderline serum vitamin B12 levels (200-400pg/ml) have   
hyperhomocysteinemia, suggestive of vitamin B12 deficiency at cellular level. 
 
 Serum homocysteine is a useful ancillary test for the diagnosis of intracellular vitamin 
B12 deficiency in patients with low normal/borderline serum vitamin B12 levels. 
 
 The most common etiology for vitamin B12 deficiency in a tertiary care hospital 
setting in  India is pernicious anemia, followed by atrophic gastritis involving fundus 
of stomach. 
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B12 STUDY-PROFORMA 
                                    -------------------------------------------------------------- 
 
NAME:                                              AGE:     yrs            SEX:  M/F                 Serial No: 
Address:                                                                            Hospital No: 
 
Phone :                                                                              Occupation: 
E mail:          
                                                                    
FINAL DIAGNOSIS (CAUSE OF B12 DEFICIENCY): 
 
PRESENTING COMPLAINTS: 
--------------------------------------------- 
1) Memory loss: Y/N 
2) Parasthesia: Y/N 
3) Motor weakness: Y/N 
4) Ataxia: Y/N 
5) Psychiatric symptoms: Y/N 
6) Skin darkening: Y/N 
7) Fatigue/malaise: Y/N 
8) Diarrhea: Y/N 
9) Anorexia: Y/N 
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PAST AND TREATMENT HISTORY: 
------------------------------------------------------- 
1) Diabetes mellitus: Y/N.   Duration:   
2) Hypertension : Y/N. Duration : 
3) IHD: Y/N. Duration: 
4) Dyslipidemia: Y/N 
5) CVA in past: Y/N 
6) Drug history: PPIs- Y/N                                                   duration :        mon 
                      H2RAs- Y/N                                               duration :        mon 
                      METFORMIN- Y/N                                   duration :        mon 
7) Smoking: Y/N 
8) Alcohol:   Y/N               Qty:            Duration:              Last intake: 
9) Diet: veg/ non-veg /vegan 
10) GI surgery: Y/N           Ind:                                          Procedure:                                                            
                                                Year: 
11) Occupational exposure: Nitrous oxide  Y/N 
                                                  Other toxins    Y/N 
EXAMINATION: 
----------------------- 
1) pallor: Y/N 
2) glossitis: Y/N 
3) oral ulcers Y/N 
4) pedal edema: Y/N 
5) skin hyperpigmentation: Y/N 
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6) RS: 
7) CVS: 
8) P/A: 
9) CNS: optic neuritis/ atrophy: 
               Peripheral neuropathy: 
               Myelopathy: 
               Hemiplegia: 
               UMN facial palsy: 
               Plantar: 
               Ataxia/ post column signs: 
               Cerebellar signs:  
               Pyramidal signs:                
10)  MMSE: 
      1) date: (year)(season)(date)(day)(month) - __/5 points 
2) Where are we: (state)(county)(town)(hospital)(floor) - __/5 points 
3) Name three objects: one second to say each. Ask the patient all three after you have said 
them. Give one point for each correct answer. Then repeat them until he/she learns all three. 
Maximum score - __/3 points.  
4) Serial 7s, beginning with 100 and counting backward: one point for each correct; stop after 
five answers. Alternatively, spell WORLD backwards: one point for each letter that is in 
correct order. Maximum score - __/5 points.  
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5) Ask for the three objects repeated above: one point for each correct. Maximum score - 
__/3 points  
6) Show and ask patient to name a pencil and wrist watch - __/2 points  
7) Repeat the following, "No ifs ands or buts." Allow only one trial - _/1 point  
8) Follow a three stage command, "Take a paper in your right hand, fold it in half, and put it 
on the floor." Score one point for each task executed. Maximum score - __/3 points  
9) On a blank piece of paper write "close your eyes," and ask the patient to read and do what 
it says - __/1 point  
10) Give the patient a blank piece of paper and ask him/her to write a sentence. The sentence 
must contain a noun and verb and be sensible. Ask him to copy a intersecting pentagon- __/2 
points 
TOTAL MMSE: __/30  
 
LAB PARAMETERS: 
1) HB:                TC:                       PLT:                       RETICS: 
2) MCV:  
 3) PERIPHERAL SMEAR: 
4) T.B/D.B:                 AG RATIO:                     LDH: 
5) VITAMIN B12:                            FOLATE: 
6) TSH:                                   
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7) URINE D-XYLOSE 
8) HIV ELISA: 
9)ANTI PARIETAL CELL Ab  -                              anti IF – 
10)ANTI TTG   +/- 
11) STOOL PARASITES-                                          OCCULT BLOOD- 
12)SERUM HOMOCYSTEINE 
OTHER RELEVANT INVESTIGATIONS: 
 
 
IMAGING STUDIES 
A.USG/CECT ABDOMEN: 
 
B.BMFT: 
 
 
 
ENDOSCOPIC EVALUATION 
A.GASTROSCOPY: 
 
B.COLONOSCOPY: 
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HISTOPATHOLOGY: 
A.STOMACH: 
 
B.DUODENUM: 
 
C.ILEUM: 
 
FOLLOW UP VISIT (after 3 months) 
1) SYMPTOMS –  IMPROVED/ NO CHANGE/ WORSENED 
 
      2)  FINDINGS     –  IMPROVED/ NO CHANGE/ WORSENED 
 
3)LABORATORY INVESTIGATIONS  - Hb          MCV 
                                                                    - VITAMIN B 12    
                                                                   -  OTHER 
4)COMPLIANCE 
 
 
 
 
 
 64 
 
INFORMED CONSENT 
 
 I understand that department of Gastrointestinal sciences, Christian Medical College, Vellore is 
doing a study to  
(i) identify the etiological factors of vitamin B12 deficiency  
(ii)compare the efficacy of oral versus parenteral vitamin B12 supplementation in subjects with 
deficiency of the vitamin,  and 
(iii) evaluate whether serum homocysteine levels can be used as a surrogate marker of intracellular 
deficiency of vitamin B12 in patients with low normal serum Vitamin B12 levels 
The study involves collection of patient information, clinical data and test reports done as part of 
regular clinical care.  I also understand that some of the tests done in connection with the study may 
directly benefit me whereas the other tests are likely to benefit other patients with the disease. 
I understand that I may receive either oral or intramuscular vitamin B12 as treatment and have been 
informed that either route of administration is equally efficacious according to the available scientific 
evidence at present. 
I understand that my withdrawal from the study, at any time will not affect the treatment being given. 
 
Study Title: COMPARISON OF EFFICACY OF ORAL VERSUS INTRAMUSCULAR 
VITAMIN B12 SUPPLEMENTATION FOR TREATMENT OF  VITAMIN B12 DEFICIENCY 
AND  DETERMINATION OF CELLULAR DEFICIENCY OF VITAMIN B12 USING SERUM 
HOMOCYSTEINE  AS A SURROGATE MARKER IN PATIENTS WITH  LOW NORMAL 
SERUM  VITAMIN B12 LEVELS 
Study Number: 
Subject’s Initials: _________ Subject’s Name: ________ 
Date of Birth / Age:_______ 
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Please initial box  
(Subject) 
(i) I confirm that I have read and understood the information sheet dated _________ for the above 
study and have had the opportunity to ask questions. [    ] 
(ii) I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time, without giving any reason, without my medical care or legal rights being 
affected. [    ] 
 (iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s behalf, the 
Ethics Committee and the regulatory authorities will not need my permission  
to look at my health records both in respect of the current study and any further research that may be 
conducted in relation to it, even if I withdraw from the trial. I agree to this access. However, I 
understand that my identity will not be revealed in any information released to third parties or 
published. [    ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided such a use is 
only for scientific purpose(s) [    ] 
(v) I agree to take part in the above study. [     ] 
Signature (or Thumb impression) of the Subject/Legally Acceptable Representative:_____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
 
Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
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KEY TO MASTERCHART 
 
I. B12 TRIAL –ORAL VS INTRAMUSCULAR TREATMENT  
(masterchart 1) 
 
• R No – random allocation number [arranged by category –intramuscular, followed by 
oral, and then followed by patients who were screened for trial, but excluded(X1-X12) 
for various reasons and considered only for etiological evluation] 
• HOS NO – hospital number 
• G – gender 
• A - age 
• State   
o TN – tamil nadu 
o WB – west bengal 
o AP – andhra pradesh 
o JHA – jharkhand 
o KAR – karnataka 
o MEGHA – meghalaya 
o TRIPU – tripura 
o CHAT - chattisgarh 
• CAT-  Category 
  1 : intramuscular treatment group 
              2 : oral treatment group 
              3 : screened, but excluded from the trial (considered only for etiology) 
• DX- Diagnosis 
o    0 : no cause identified 
o    1 : pernicious anaemia 
o    2 : caeliac sprue 
o    3 : tropical sprue/enteropathy 
o    4 : inflammatory bowel disease (A-Crohns disease, B-ulcerative colitis) 
o    5 : vegetarian diet 
o    6 : drug (A-PPI,B-H2RA,C-METFORMIN) 
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o    7 : atrophic gastritis (A- Hpylori related, B- Non Hpylori related) 
o    8 : pancreatic exocrine insufficiency 
o    9 : ileal surgery 
• S – symptoms (1=present,2=absent) 
• S1 – memory disturbances (1=present,2=absent) 
• S2 – parasthesias (1=present,2=absent) 
• S3 – psychiatric disturbances (1=present,2=absent) 
• S4 – skin hyperpigmentation (1=present,2=absent) 
• S5 – fatigue/malaise (1=present,2=absent) 
• S6 – diarrhea (1=present,2=absent) 
• S7 – anorexia (1=present,2=absent) 
• DM – diabetes mellitus (1=present,2=absent) 
• HT – hypertension (1=present,2=absent) 
• IHD – ischaemic heart disease 
• DL – dyslipidemia (1=present,2=absent) 
• CV – cerebrovascular accident (1=present,2=absent) 
• D1 – proton pump inhibitor use (1=present,2=absent) 
• D2 – metformin use (1=present,2=absent) 
• SM- smoking (1=present,2=absent) 
• AL-alcohol abuse(1=present,2=absent) 
• DE- diet (1-vegetarian,2-nonvegetarian) 
• SX – ileal surgery 
• F1 – pallor (1=present,2=absent) 
• F2 - glossitis (1=present,2=absent) 
• F3 – oral ulcers (1=present,2=absent) 
• F4 – neurological findings (1=present,2=absent) 
• HB1- pretreatment haemoglobin(g/dl) 
• HB2 – posttreatment haemoglobin(g/dl) 
• MC1 – pretreatment mean corpuscular volume(fl) 
• MC2 – posttreatment mean corpuscular volume(fl) 
• B12A - pretreatment serum vitamin B12(pg/ml) 
• B12B - posttreatment serum vitamin B12(pg/ml) 
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• HC1 – pretreatment serum homocysteine (µM/L) 
• HC2 – posttreatment serum homocysteine (µM/L) 
• RX – treatment response (1=responded, 2=not responded) 
• AP – antiparietal cell antibody (1=present,2=absent) 
• IF  – antiintrinsic factor antibody (1=present,2=absent) 
•  TTG– anti tissue transglutaminase antibody (1=present,2=absent) 
• SP- stool parasites(1=present,2=absent) 
• HPA – histopathology of antrum, HPF- histopathology of fundus (stomach) 
o 1- normal 
o 2- chronic atrophic gastritis, Hpylori related 
o 3- chronic atrophic gastritis, non Hpylori related 
o 4- autoimmune gastritis 
o 5- other 
• HPD – histopathology of duodenum, HPI – histopathology of ileum 
o N- normal 
o X –   data not available 
• HP – Helicobacter pylori (1=present,2=absent) 
• SUB – subjective improvement (1=improved, 2=worsened, 3=no change) 
• COM – compliance (%)  
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II. VITAMIN B12 – HOMOCYSTEINE CORRELATION (masterchart 2) 
 
• H No – Hospital number 
• State   
o TN – tamil nadu 
o WB – west bengal 
o AP – andhra pradesh 
o JHA – jharkhand 
o KAR – karnataka 
o ORI – orissa 
o MEGHA – meghalaya 
o TRIPU – tripura 
o CHAT - chattisgarh 
o BAN - bangladesh 
• HB – haemoglobin (g/dl) 
• MCV – mean corpuscular volume (fl) 
• B12 – serum vitamin B12 (pg/ml) 
• HCY – serum homocysteine (µM/L) 
• PSY – psychiatric symptoms (1=present,2=absent) 
• SKI – skin hyperpigmentation (1=present,2=absent) 
• MAL – fatigue/malaise (1=present,2=absent)  
• DIA – diarrhea (1=present,2=absent) 
• AX – anorexia (1=present,2=absent) 
• H2R – H2 receptor antagonist use (1=present, 2=absent) 
• MET – metformin use (1=present,2=absent) 
• DIET - (1=vegetarian,2=non vegetarian) 
• SUR- ileal surgery (1=yes,2=no) 
• PAL – pallor (1=present,2=absent) 
• GL – glossitis (1=present,2=absent)  
• OR – oral ulcers (1=present,2=absent) 
• STOMACH/DUODENAL HISTOLOGY (X –data not available) 
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R NoNAME HOS NO G A STATE CATDX S S1 S2 S3 S4 S5 S6 S7 DM HT IHD DL CV D1 D2 SM AL DE SX F1 F2 F3 F4 HB1 HB2 MC1 MC2 B12A B12B HC1 HC2 RX AP IF SP TTGHPA HPF HPD HPI HP SUB COM
1 KRISHNA PRASAD RAJA 575993D M 44 KERALA 1 1,5 1 2 2 2 2 1 2 1 2 2 2 2 2 2 2 1 2 1 2 2 2 2 2 13.1 13.3 88 86.2 157.2 1005 13.2 X 1 2 1 2 1 3 3 N X 2 1 100
3 BASANTH MAHTO 589418D M 47 JHA 1 7A 1 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 6.1 6.9 81.6 90.9 197.7 1495 X 5.9 1 2 2 1 2 2 2 MILD CHRONIC DUODENITIS X 1 1 100
8 SANKAR KUMAR GHOSH 316650D M 57 WB 1 7A 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 12.3 14.1 93.1 94.7 189 1284 X 21 1 1 2 2 2 2 2 N N 1 1 100
9 SULEKHA DEY 610095D F 44 ASSAM 1 7A 1 2 2 2 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 9.8 8.4 59.7 59 124.9 381.4 31.9 X 1 2 2 2 1 2 2 N X 1 3 80
10 SEKAR J 576351D M 42 AP 1 5,7A 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 15.5 15 94.5 93.2 131.3 772.3 22.5 15.4 1 2 2 2 2 2 2 N N 1 3 100
12 RAGHUNATH REDDY 609122D M 43 AP 1 2,7A 1 2 1 2 1 1 1 1 2 2 2 2 2 2 2 1 1 2 2 1 2 2 1 6.6 15.4 129 X 78.01 680.5 94.6 X 1 2 2 2 1 2 2 MILD VILLOUS ATROPHY N 1 1 100
15 ANUGRAH N SINGH  618868D M 51 JHA 1 2 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 9.9 13.5 110 87.8 88.04 293.4 42.5 X 1 2 2 2 2 3 3 SUBTOTAL VILLOUS ATROPHY N 2 1 100
16 ANTAKA TAMANG 617252D F 38 WB 1 1,6A 1 2 2 2 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 12.1 12.2 89.3 85.7 194.1 843.3 22 1 1 2 2 2 2 2 MILD CHRONIC DUODENITIS N 1 1 100
17 SURESH KUMAR PATEL 437690D M 43 MP 1 7A 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 13.1 X 94.4 X 187.9 X 15.2 X 2 2 2 2 2 2 2 N N 1 X X
18 MENUKA DANGAL 627493D F 43 NEPAL 1 0 1 2 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 13.1 13.1 98.8 94.2 197.4 1858 14 9.81 1 2 2 1 2 1 1 N X 2 1 100
20 KATHIRVEL S 598782D M 57 TN 1 5,6C 2 2 2 2 2 2 2 2 1 1 2 2 2 2 1 2 2 1 2 2 2 2 2 14.5 12.2 87.9 85.7 138 843.3 32.7 X 1 2 2 2 2 2 2 N N 1 3 100
23 SUSANTHA MONDAL 647840B M 42 WB 1 1 1 2 2 2 2 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 13.2 14 85.8 88.2 196 948.7 X X 1 1 2 2 2 2 2 MILD CHRONIC DUODENITIS MILD ACTIVE ILEITIS 1 3 100
25 PRABIR KUMAR ROY 653180D M 44 WB 1 1 1 2 2 2 2 1 1 2 2 1 2 2 2 2 2 1 2 2 2 2 2 2 2 11.1 12.5 82.9 75.2 160.7 1577 59.7 X 1 2 1 2 2 2 5 N N 1 1 100
26 SYED SHAID R 665073D M 36 TN 1 3 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 1 1 2 2 2 2 2 2 14.9 18.3 118 100 97.55 209.6 X X 1 1 2 2 2 2 1 INCREASED IEL,VILLOUS ATROPHYX 1 1 100
29 PRASAD AL 623593D M 41 JHA 1 6B,7A 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 13.8 12.9 86.4 86.4 136.6 888.1 29.2 X 1 2 2 2 1 2 2 MILD CHRONIC DUODENITIS N 1 1 100
33 ARUN KUMAR TANTI 391770D M 42 JHA 1 0 1 2 2 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 12.4 14.1 91.4 78 96.2 860.4 39.9 X 1 2 2 2 1 1 1 N N 2 1 100
34 ANJU DEVI 654619D M 40 JHA 1 0 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 10.3 12.4 75 85 126.5 1029 16.2 X 1 2 2 2 1 1 1 N N 2 1 100
35 RADHE SHYAM MANDAL 186959D M 53 NEPAL 1 5 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 13.3 13.5 95.8 92.3 136.8 1420 25.5 X 1 2 2 2 2 2 1 N N 1 1 90
36 CHINNA THAMBI 701111A M 47 TN 1 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2 2 8.9 13.1 62 X 140.2 1460 X X 1 1 1 2 2 4 4 LYMPHANGEIECTASIS N 2 1 100
41 PARIMALA 641784D F 40 AP 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 8.4 13.1 70.8 85.7 86 340.5 X 9 1 1 1 2 2 4 1 X X 2 3 100
42 BIPUL ROY 709948D M 30 WB 1 0 1 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 14.1 14.9 88 87.6 189.8 930.6 49 X 1 2 2 2 2 2 1 N N 1 1 100
44 DEBABRATA DEY 914627C M 61 WB 1 2 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 11.2 11.7 119 93.6 179.5 2000 X X 1 2 2 2 1 1 5 INCREASED IEL,VILLOUSATROPH MILD CHRONIC ILEITIS 2 1 100
46 DHAMAYANTHI 702010D M 39 TN 1 1 1 2 2 2 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 9 X 64.6 X 172.5 X X X 2 1 2 1 2 2 2 N X 1 X X
48 SAMPATH S 562950D M 54 TN 1 6A,7A 1 2 1 2 2 1 2 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 14.6 X 89.5 X 170.3 X X X 2 2 2 2 2 2 2 MILD CHRONIC DUODENITIS N 1 X X
51 JAGADISH PRASAD SAH 717824D M 65 JHA 1 7A 1 2 2 2 2 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 14 14.2 71.3 73 184.9 2000 22.5 X 1 2 2 2 2 2 2 N N 1 1 100
52 BIKAS KUMAR SAHU 723577D M 29 JHA 1 7A 1 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 14.5 14.1 92.6 88.3 166.5 2000 17.4 11.3 1 2 2 2 2 2 2 N N 1 1 100
53 JOTHI LINGAM 293387D M 50 TN 1 1,5 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 14.7 14.3 97.6 89.4 97.09 2000 X X 1 1 2 2 2 5 5 N N 2 1 100
57 DHAKSHANOMOORTHI 654584D F 34 TN 1 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 15.8 15 94.3 86.2 184.1 1011 15 X 1 1 2 2 2 2 2 N N 1 1 100
59 MAHENDRA SINGH BISHT 747960D M 51 CHAT 1 9 1 2 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 15.3 14.5 X X 50.45 1377 X X 1 1 2 2 2 3 3 N MILD CHRONIC ILEITIS 2 1 100
60 GOPAL RAO R 762321D M 24 CHAT 1 1 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 15.4 16.3 79.6 79.9 125.8 956.3 41 X 1 2 1 2 2 2 5 N N 1 1 90
2 SARAVANAN M 471116D M 29 TN 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 1 1 2 2 2 2 2 2 14.9 X 101 X 92.78 X 31.6 X 2 2 2 1 1 2 1 MILD CHRONIC DUODENITIS MILD VILLOUS ATROPHY 1 X X
4 RAVI PRASAD TIWARI 562944D M 25 JHA 2 1 1 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 16 14.6 96.4 93.4 165.4 168.8 16.5 X 2 1 2 2 2 2 2 N MILDEOSNOPHILICILEITIS 1 1 80
5 SARASWATHY 803373B F 23 TN 2 0 1 2 2 2 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 12 11.3 95.6 95.5 199.2 421.9 32 12 1 2 2 1 1 2 1 N X 1 1 100
6 LAKSHMI NARAYANAN 588681D M 58 TN 2 5 1 2 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 1 2 2 2 2 2 13.9 X 87.2 X 191.7 X 28.2 X 2 2 2 1 2 2 2 N N 1 X X
7 VICTORIA 344627 F 39 TN 2 1,6C 2 2 2 2 2 2 2 2 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 8.6 11.5 81.5 92.2 112.5 739.4 25 X 1 1 2 2 2 2 2 N N 1 1 100
11 MUNASWAMY NAIDU 587924D M 56 AP 2 3 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 13.4 12.2 98.5 94.5 149.9 623.7 30.2 21.5 1 1 2 1 2 3 1 MILD CHRONIC DUODENITIS N 2 1 100
13 MANTU SHARMA 601655D M 22 JHA 2 7A 1 2 2 2 2 2 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 13.9 X 88.6 X 180.3 X 16.5 X 2 2 2 2 2 2 2 N CHRONIC ACTIVE ILEITIS 1 X X
14 JAMBU LINGAM A K 364766B M 66 TN 2 3 1 2 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 11.6 15.7 94.9 94.2 130 175.8 53.7 X 2 2 2 2 2 2 1 MILD CDUODENITIS, VILLOUS ATR N 1 1 100
19 SHOBHA JAIN 610165D F 46 BIHAR 2 5 1 2 2 2 2 1 1 2 2 1 2 2 2 2 2 2 2 1 2 2 2 2 2 11 11.2 86.3 84.4 195.8 662 26.5 7.34 1 X X 2 1 5 5 N N 2 3 100
21 KRISHNAVENI SIRIBOYINA 631316D F 33 AP 2 7A 1 2 2 2 2 1 1 1 1 1 1 1 1 2 2 2 2 2 2 1 2 2 2 9.8 10.1 94.2 93 83 293 57.1 X 1 2 2 2 2 2 3 N N 1 1 100
22 NAROTTAM SAHOO 842497B M 41 ORISSA 2 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 8.7 9.8 74.6 74 163.9 339.5 32.4 X 1 1 2 2 2 2 3 N PROMINENT LYMPHOID F 1 1 90
24 PINTU KHETAN 654648D M 28 ASSAM 2 2,7A 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 1 2 1 2 2 2 8.9 X 129 X 125.2 X 61 X 2 2 2 2 1 2 2 MODERATE VILLOUS ATROPHY INCREASED IEL 1 X X
27 BAGAVATHI 736460A F 65 AP 2 7A 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 1 2 2 2 8.3 13 70.3 90.6 179.6 229.4 22 X 1 2 2 2 2 2 2 N X 1 1 100
28 SAUNDAR RANI G 067144D F 48 TN 2 7A 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 9.2 9 X 69.1 194.4 314.1 9.5 6.3 1 2 2 2 2 2 2 N N 1 3 90
30 MEERA SINGH 656261D F 35 JHA 2 2 1 2 2 2 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 8.1 13 133 82.4 163.1 507 41.8 X 1 2 2 2 1 3 1 MILD CDUODENITIS, HIGH IEL X 2 1 100
31 ISWARA MAHARANA 078890D M 52 ORISSA 2 1 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 10.5 X 102 X 123.6 X 56 X 2 1 2 2 2 2 2 N N 1 X X
32 PULIN CHANDRA SADHU 656194D M 63 WB 2 3 1 2 2 2 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 10 11.5 89 89.5 148.9 652.4 24.6 7.8 1 2 2 2 2 3 1 N N 2 1 100
37 VINAYAGAM P 623789D M 29 TN 2 3 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 14.4 15.7 93.7 95.7 175.2 581.3 26.5 X 1 2 2 2 2 1 1 N MILD ACUTE ILEITIS 2 1 100
38 ANIL KUMAR MANDAL 540702D M 45 JHA 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 11.2 13.2 110 91.9 94.46 498.8 X 11.8 1 1 2 2 1 5 3 N X 2 1 90
39 PREETHAM SAMUEL 7293000DM 32 TN 2 1 1 2 2 2 1 1 1 1 2 2 2 2 2 2 2 1 1 2 2 2 2 2 2 11.8 X 90.8 X 135.3 X X X 2 1 1 2 2 4 4 N X 2 X X
40 MANJUNATHAN D 750023B M 28 TN 2 1,5 1 2 2 2 1 1 2 1 2 2 2 2 2 2 2 2 2 1 2 1 2 2 2 9.7 12.4 X 73.4 48.58 387.5 134 X 1 1 2 2 2 5 3 N N 2 1 100
43 KANAKARAO 714518D M 23 AP 2 0 1 2 1 2 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 16.8 16.9 89.9 82.9 136.7 675.4 42.8 30.5 1 2 2 2 2 1 1 N N 2 1 100
45 BHABANI UPADHAYAYA 737864D F 51 TN 2 1,3 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 13.1 13.8 91.9 93.6 153.8 593.4 X 23.6 1 1 2 2 2 2 3 INCREASED IEL,VILLOUS ATROPHYN 1 1 90
47 SARANYA 010013B F 18 TN 2 0 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 10 12.7 66.9 79.6 134.3 623 38 X 1 2 2 2 2 1 1 N X 2 1 100
49 SELVARANI A 798784C F 24 TN 2 0 2 2 2 2 2 2 1 1 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2 9.9 11.1 87 85 175.8 476.2 23.3 X 1 2 2 X 2 2 1 N ACUTE ILEITIS 1 1 100
50 ANIL KUMAR MAHATO 782527D M 21 WB 2 7A 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 13.8 14 98.9 94.5 145 543.4 X X 1 2 2 1 2 2 2 N N 1 3 100
54 ANIL KUMAR 774756D M 35 BIHAR 2 5 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 12.8 X 88.8 X 187.5 X X X 2 2 2 1 2 1 1 INCREASED IEL N 2 X X
55 APURBA KUMAR SHARMA 723845D M 37 WB 2 7A 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 14.3 14.2 93.9 92.4 199 683.3 X 11.8 1 2 2 2 2 2 5 X X 1 1 100
56 DEEPAK S 526554A M 25 TN 2 1 1 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 12.9 14.1 80.8 79.7 168.7 556.3 26 12.4 1 1 1 2 2 1 1 N N 2 1 100
58 SAKUNTHALA K 190768D F 62 TN 2 9 1 2 2 2 2 2 1 2 1 1 2 2 2 2 2 2 2 2 1 2 2 2 2 11.3 X 83.8 X 141 X X X 2 2 2 2 2 3 3 N N 2 X X
X1 DEVAKI 124100C F 51 TN 3 1,6A 1 2 2 2 2 1 2 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 12 X 83.4 X 112.7 X 21.2 X X 1 1 2 1 2 3 N X 1 X X
X2 AKILESH KUMAR SINGH 578322D M 46 JHA 3 7B 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 12.3 X 93.8 X 167.8 X 12.5 X X 2 2 2 2 3 3 MILD DUODENITIS N 2 X X
X3 SUBRAMANI C 261369C M 58 TN 3 1 1 2 2 2 2 1 2 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 16.2 X 93.6 X 126.9 X 16.5 X X 1 2 2 2 5 5 N X 2 X X
X4 PYNHUNLANG LYNGDOH 614845D M 18 MEGHA 3 7B 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 15 X 88.3 X 173.3 X 19 X X 2 2 2 2 3 3 N N 2 X X
X5 TOTAN CHAKRABORTHY 647471D M 34 TRIPU 3 7A 1 2 2 2 2 2 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 13.1 X 69 X 161.4 X 17.8 X X 2 2 2 2 2 2 N N 1 X X
X6 LAKHAN LAL BARNWAL 587064D M 50 JHA 3 1,5 1 2 1 2 2 2 2 1 2 1 2 2 2 1 2 2 2 1 2 2 2 2 2 12.2 X 83.5 X 143.3 X 19.1 X X 1 2 2 2 2 5 N N 1 X X
X7 DEBURANJAN MOZUMDER 152795C M 47 WB 3 7A 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 14.2 X X X 133 X 43.6 X X 2 2 2 2 2 2 N CHRONIC ACTIVE ILEITIS 1 X X
X8 SHASHI KALA DEVI 710386D F 46 JHA 3 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 12.3 X 87.2 X 125.2 X 18.2 X X 2 1 2 2 2 2 N MINIMAL ACUTE ILEITIS 1 X X
X9 SRINIVASAN B 684799C M 46 TN 3 1,5 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 15.1 X 108 X 86.22 X X X X 1 2 2 1 2 2 MILD CHRONIC DUODENITIS X 1 X X
X10 KARPAGAM 782465D F 49 TN 3 8,4B 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 8.1 X 63.4 X 144.2 X X X X 2 2 2 X 2 3 N CHRONIC ACTIVE ILEITIS 1 X X
X11 MANOJ PANDEY 519746D M 29 JHA 3 1 1 2 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 15.4 X 80.4 X 189 X X X X 1 1 2 2 2 2 N PROMINENT LYMPHOID F 1 X X
X12 MALAY KUMAR 557236D M 47 WB 3 1 1 2 2 2 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 8.3 X 122 X 62.48 X X X X 1 1 2 2 3 3 N N 2 X X
B12 TRIAL-ORAL VS INTRAMUSCULAR TREATMENT (MASTERCHART 1) 70
R NoNAME HOS NO G A STATE CATDX S S1 S2 S3 S4 S5 S6 S7 DM HT IHD DL CV D1 D2 SM AL DE SX F1 F2 F3 F4 HB1 HB2 MC1 MC2 B12A B12B HC1 HC2 RX AP IF SP TTGHPA HPF HPD HPI HP SUB COM
1 KRISHNA PRASAD RAJA 575993D M 44 KERALA 1 1,5 1 2 2 2 2 1 2 1 2 2 2 2 2 2 2 1 2 1 2 2 2 2 2 13.1 13.3 88 86.2 157.2 1005 13.2 X 1 2 1 2 1 3 3 N X 2 1 100
3 BASANTH MAHTO 589418D M 47 JHA 1 7A 1 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 6.1 6.9 81.6 90.9 197.7 1495 X 5.9 1 2 2 1 2 2 2 MILD CHRONIC DUODENITIS X 1 1 100
8 SANKAR KUMAR GHOSH 316650D M 57 WB 1 7A 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 12.3 14.1 93.1 94.7 189 1284 X 21 1 1 2 2 2 2 2 N N 1 1 100
9 SULEKHA DEY 610095D F 44 ASSAM 1 7A 1 2 2 2 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 9.8 8.4 59.7 59 124.9 381.4 31.9 X 1 2 2 2 1 2 2 N X 1 3 80
10 SEKAR J 576351D M 42 AP 1 5,7A 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 15.5 15 94.5 93.2 131.3 772.3 22.5 15.4 1 2 2 2 2 2 2 N N 1 3 100
12 RAGHUNATH REDDY 609122D M 43 AP 1 2,7A 1 2 1 2 1 1 1 1 2 2 2 2 2 2 2 1 1 2 2 1 2 2 1 6.6 15.4 129 X 78.01 680.5 94.6 X 1 2 2 2 1 2 2 MILD VILLOUS ATROPHY N 1 1 100
15 ANUGRAH N SINGH  618868D M 51 JHA 1 2 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 9.9 13.5 110 87.8 88.04 293.4 42.5 X 1 2 2 2 2 3 3 SUBTOTAL VILLOUS ATROPHY N 2 1 100
16 ANTAKA TAMANG 617252D F 38 WB 1 1,6A 1 2 2 2 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 12.1 12.2 89.3 85.7 194.1 843.3 22 1 1 2 2 2 2 2 MILD CHRONIC DUODENITIS N 1 1 100
17 SURESH KUMAR PATEL 437690D M 43 MP 1 7A 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2 2 2 2 2 13.1 X 94.4 X 187.9 X 15.2 X 2 2 2 2 2 2 2 N N 1 X X
18 MENUKA DANGAL 627493D F 43 NEPAL 1 0 1 2 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 13.1 13.1 98.8 94.2 197.4 1858 14 9.81 1 2 2 1 2 1 1 N X 2 1 100
20 KATHIRVEL S 598782D M 57 TN 1 5,6C 2 2 2 2 2 2 2 2 1 1 2 2 2 2 1 2 2 1 2 2 2 2 2 14.5 12.2 87.9 85.7 138 843.3 32.7 X 1 2 2 2 2 2 2 N N 1 3 100
23 SUSANTHA MONDAL 647840B M 42 WB 1 1 1 2 2 2 2 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 13.2 14 85.8 88.2 196 948.7 X X 1 1 2 2 2 2 2 MILD CHRONIC DUODENITIS MILD ACTIVE ILEITIS 1 3 100
25 PRABIR KUMAR ROY 653180D M 44 WB 1 1 1 2 2 2 2 1 1 2 2 1 2 2 2 2 2 1 2 2 2 2 2 2 2 11.1 12.5 82.9 75.2 160.7 1577 59.7 X 1 2 1 2 2 2 5 N N 1 1 100
26 SYED SHAID R 665073D M 36 TN 1 3 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 1 1 2 2 2 2 2 2 14.9 18.3 118 100 97.55 209.6 X X 1 1 2 2 2 2 1 INCREASED IEL,VILLOUS ATROPHYX 1 1 100
29 PRASAD AL 623593D M 41 JHA 1 6B,7A 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 13.8 12.9 86.4 86.4 136.6 888.1 29.2 X 1 2 2 2 1 2 2 MILD CHRONIC DUODENITIS N 1 1 100
33 ARUN KUMAR TANTI 391770D M 42 JHA 1 0 1 2 2 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 12.4 14.1 91.4 78 96.2 860.4 39.9 X 1 2 2 2 1 1 1 N N 2 1 100
34 ANJU DEVI 654619D M 40 JHA 1 0 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 10.3 12.4 75 85 126.5 1029 16.2 X 1 2 2 2 1 1 1 N N 2 1 100
35 RADHE SHYAM MANDAL 186959D M 53 NEPAL 1 5 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 13.3 13.5 95.8 92.3 136.8 1420 25.5 X 1 2 2 2 2 2 1 N N 1 1 90
36 CHINNA THAMBI 701111A M 47 TN 1 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2 2 8.9 13.1 62 X 140.2 1460 X X 1 1 1 2 2 4 4 LYMPHANGEIECTASIS N 2 1 100
41 PARIMALA 641784D F 40 AP 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 8.4 13.1 70.8 85.7 86 340.5 X 9 1 1 1 2 2 4 1 X X 2 3 100
42 BIPUL ROY 709948D M 30 WB 1 0 1 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 14.1 14.9 88 87.6 189.8 930.6 49 X 1 2 2 2 2 2 1 N N 1 1 100
44 DEBABRATA DEY 914627C M 61 WB 1 2 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 11.2 11.7 119 93.6 179.5 2000 X X 1 2 2 2 1 1 5 INCREASED IEL,VILLOUSATROPH MILD CHRONIC ILEITIS 2 1 100
46 DHAMAYANTHI 702010D M 39 TN 1 1 1 2 2 2 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 9 X 64.6 X 172.5 X X X 2 1 2 1 2 2 2 N X 1 X X
48 SAMPATH S 562950D M 54 TN 1 6A,7A 1 2 1 2 2 1 2 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 14.6 X 89.5 X 170.3 X X X 2 2 2 2 2 2 2 MILD CHRONIC DUODENITIS N 1 X X
51 JAGADISH PRASAD SAH 717824D M 65 JHA 1 7A 1 2 2 2 2 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 14 14.2 71.3 73 184.9 2000 22.5 X 1 2 2 2 2 2 2 N N 1 1 100
52 BIKAS KUMAR SAHU 723577D M 29 JHA 1 7A 1 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 14.5 14.1 92.6 88.3 166.5 2000 17.4 11.3 1 2 2 2 2 2 2 N N 1 1 100
53 JOTHI LINGAM 293387D M 50 TN 1 1,5 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 14.7 14.3 97.6 89.4 97.09 2000 X X 1 1 2 2 2 5 5 N N 2 1 100
57 DHAKSHANOMOORTHI 654584D F 34 TN 1 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 15.8 15 94.3 86.2 184.1 1011 15 X 1 1 2 2 2 2 2 N N 1 1 100
59 MAHENDRA SINGH BISHT 747960D M 51 CHAT 1 9 1 2 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 15.3 14.5 X X 50.45 1377 X X 1 1 2 2 2 3 3 N MILD CHRONIC ILEITIS 2 1 100
60 GOPAL RAO R 762321D M 24 CHAT 1 1 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 15.4 16.3 79.6 79.9 125.8 956.3 41 X 1 2 1 2 2 2 5 N N 1 1 90
2 SARAVANAN M 471116D M 29 TN 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 1 1 2 2 2 2 2 2 14.9 X 101 X 92.78 X 31.6 X 2 2 2 1 1 2 1 MILD CHRONIC DUODENITIS MILD VILLOUS ATROPHY 1 X X
4 RAVI PRASAD TIWARI 562944D M 25 JHA 2 1 1 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 16 14.6 96.4 93.4 165.4 168.8 16.5 X 2 1 2 2 2 2 2 N MILDEOSNOPHILICILEITIS 1 1 80
5 SARASWATHY 803373B F 23 TN 2 0 1 2 2 2 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 12 11.3 95.6 95.5 199.2 421.9 32 12 1 2 2 1 1 2 1 N X 1 1 100
6 LAKSHMI NARAYANAN 588681D M 58 TN 2 5 1 2 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 1 2 2 2 2 2 13.9 X 87.2 X 191.7 X 28.2 X 2 2 2 1 2 2 2 N N 1 X X
7 VICTORIA 344627 F 39 TN 2 1,6C 2 2 2 2 2 2 2 2 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 8.6 11.5 81.5 92.2 112.5 739.4 25 X 1 1 2 2 2 2 2 N N 1 1 100
11 MUNASWAMY NAIDU 587924D M 56 AP 2 3 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 13.4 12.2 98.5 94.5 149.9 623.7 30.2 21.5 1 1 2 1 2 3 1 MILD CHRONIC DUODENITIS N 2 1 100
13 MANTU SHARMA 601655D M 22 JHA 2 7A 1 2 2 2 2 2 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 13.9 X 88.6 X 180.3 X 16.5 X 2 2 2 2 2 2 2 N CHRONIC ACTIVE ILEITIS 1 X X
14 JAMBU LINGAM A K 364766B M 66 TN 2 3 1 2 2 2 2 2 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 11.6 15.7 94.9 94.2 130 175.8 53.7 X 2 2 2 2 2 2 1 MILD CDUODENITIS, VILLOUS ATR N 1 1 100
19 SHOBHA JAIN 610165D F 46 BIHAR 2 5 1 2 2 2 2 1 1 2 2 1 2 2 2 2 2 2 2 1 2 2 2 2 2 11 11.2 86.3 84.4 195.8 662 26.5 7.34 1 X X 2 1 5 5 N N 2 3 100
21 KRISHNAVENI SIRIBOYINA 631316D F 33 AP 2 7A 1 2 2 2 2 1 1 1 1 1 1 1 1 2 2 2 2 2 2 1 2 2 2 9.8 10.1 94.2 93 83 293 57.1 X 1 2 2 2 2 2 3 N N 1 1 100
22 NAROTTAM SAHOO 842497B M 41 ORISSA 2 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 8.7 9.8 74.6 74 163.9 339.5 32.4 X 1 1 2 2 2 2 3 N PROMINENT LYMPHOID F 1 1 90
24 PINTU KHETAN 654648D M 28 ASSAM 2 2,7A 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 1 2 1 2 2 2 8.9 X 129 X 125.2 X 61 X 2 2 2 2 1 2 2 MODERATE VILLOUS ATROPHY INCREASED IEL 1 X X
27 BAGAVATHI 736460A F 65 AP 2 7A 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 1 2 2 2 8.3 13 70.3 90.6 179.6 229.4 22 X 1 2 2 2 2 2 2 N X 1 1 100
28 SAUNDAR RANI G 067144D F 48 TN 2 7A 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 9.2 9 X 69.1 194.4 314.1 9.5 6.3 1 2 2 2 2 2 2 N N 1 3 90
30 MEERA SINGH 656261D F 35 JHA 2 2 1 2 2 2 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 8.1 13 133 82.4 163.1 507 41.8 X 1 2 2 2 1 3 1 MILD CDUODENITIS, HIGH IEL X 2 1 100
31 ISWARA MAHARANA 078890D M 52 ORISSA 2 1 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 10.5 X 102 X 123.6 X 56 X 2 1 2 2 2 2 2 N N 1 X X
32 PULIN CHANDRA SADHU 656194D M 63 WB 2 3 1 2 2 2 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 10 11.5 89 89.5 148.9 652.4 24.6 7.8 1 2 2 2 2 3 1 N N 2 1 100
37 VINAYAGAM P 623789D M 29 TN 2 3 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 14.4 15.7 93.7 95.7 175.2 581.3 26.5 X 1 2 2 2 2 1 1 N MILD ACUTE ILEITIS 2 1 100
38 ANIL KUMAR MANDAL 540702D M 45 JHA 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 11.2 13.2 110 91.9 94.46 498.8 X 11.8 1 1 2 2 1 5 3 N X 2 1 90
39 PREETHAM SAMUEL 7293000DM 32 TN 2 1 1 2 2 2 1 1 1 1 2 2 2 2 2 2 2 1 1 2 2 2 2 2 2 11.8 X 90.8 X 135.3 X X X 2 1 1 2 2 4 4 N X 2 X X
40 MANJUNATHAN D 750023B M 28 TN 2 1,5 1 2 2 2 1 1 2 1 2 2 2 2 2 2 2 2 2 1 2 1 2 2 2 9.7 12.4 X 73.4 48.58 387.5 134 X 1 1 2 2 2 5 3 N N 2 1 100
43 KANAKARAO 714518D M 23 AP 2 0 1 2 1 2 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 16.8 16.9 89.9 82.9 136.7 675.4 42.8 30.5 1 2 2 2 2 1 1 N N 2 1 100
45 BHABANI UPADHAYAYA 737864D F 51 TN 2 1,3 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 13.1 13.8 91.9 93.6 153.8 593.4 X 23.6 1 1 2 2 2 2 3 INCREASED IEL,VILLOUS ATROPHYN 1 1 90
47 SARANYA 010013B F 18 TN 2 0 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 10 12.7 66.9 79.6 134.3 623 38 X 1 2 2 2 2 1 1 N X 2 1 100
49 SELVARANI A 798784C F 24 TN 2 0 2 2 2 2 2 2 1 1 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2 9.9 11.1 87 85 175.8 476.2 23.3 X 1 2 2 X 2 2 1 N ACUTE ILEITIS 1 1 100
50 ANIL KUMAR MAHATO 782527D M 21 WB 2 7A 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 13.8 14 98.9 94.5 145 543.4 X X 1 2 2 1 2 2 2 N N 1 3 100
54 ANIL KUMAR 774756D M 35 BIHAR 2 5 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 12.8 X 88.8 X 187.5 X X X 2 2 2 1 2 1 1 INCREASED IEL N 2 X X
55 APURBA KUMAR SHARMA 723845D M 37 WB 2 7A 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 14.3 14.2 93.9 92.4 199 683.3 X 11.8 1 2 2 2 2 2 5 X X 1 1 100
56 DEEPAK S 526554A M 25 TN 2 1 1 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 12.9 14.1 80.8 79.7 168.7 556.3 26 12.4 1 1 1 2 2 1 1 N N 2 1 100
58 SAKUNTHALA K 190768D F 62 TN 2 9 1 2 2 2 2 2 1 2 1 1 2 2 2 2 2 2 2 2 1 2 2 2 2 11.3 X 83.8 X 141 X X X 2 2 2 2 2 3 3 N N 2 X X
X1 DEVAKI 124100C F 51 TN 3 1,6A 1 2 2 2 2 1 2 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 12 X 83.4 X 112.7 X 21.2 X X 1 1 2 1 2 3 N X 1 X X
X2 AKILESH KUMAR SINGH 578322D M 46 JHA 3 7B 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 12.3 X 93.8 X 167.8 X 12.5 X X 2 2 2 2 3 3 MILD DUODENITIS N 2 X X
X3 SUBRAMANI C 261369C M 58 TN 3 1 1 2 2 2 2 1 2 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 16.2 X 93.6 X 126.9 X 16.5 X X 1 2 2 2 5 5 N X 2 X X
X4 PYNHUNLANG LYNGDOH 614845D M 18 MEGHA 3 7B 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 15 X 88.3 X 173.3 X 19 X X 2 2 2 2 3 3 N N 2 X X
X5 TOTAN CHAKRABORTHY 647471D M 34 TRIPU 3 7A 1 2 2 2 2 2 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 13.1 X 69 X 161.4 X 17.8 X X 2 2 2 2 2 2 N N 1 X X
X6 LAKHAN LAL BARNWAL 587064D M 50 JHA 3 1,5 1 2 1 2 2 2 2 1 2 1 2 2 2 1 2 2 2 1 2 2 2 2 2 12.2 X 83.5 X 143.3 X 19.1 X X 1 2 2 2 2 5 N N 1 X X
X7 DEBURANJAN MOZUMDER 152795C M 47 WB 3 7A 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 14.2 X X X 133 X 43.6 X X 2 2 2 2 2 2 N CHRONIC ACTIVE ILEITIS 1 X X
X8 SHASHI KALA DEVI 710386D F 46 JHA 3 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 12.3 X 87.2 X 125.2 X 18.2 X X 2 1 2 2 2 2 N MINIMAL ACUTE ILEITIS 1 X X
X9 SRINIVASAN B 684799C M 46 TN 3 1,5 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 15.1 X 108 X 86.22 X X X X 1 2 2 1 2 2 MILD CHRONIC DUODENITIS X 1 X X
X10 KARPAGAM 782465D F 49 TN 3 8,4B 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 8.1 X 63.4 X 144.2 X X X X 2 2 2 X 2 3 N CHRONIC ACTIVE ILEITIS 1 X X
X11 MANOJ PANDEY 519746D M 29 JHA 3 1 1 2 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 15.4 X 80.4 X 189 X X X X 1 1 2 2 2 2 N PROMINENT LYMPHOID F 1 X X
X12 MALAY KUMAR 557236D M 47 WB 3 1 1 2 2 2 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 8.3 X 122 X 62.48 X X X X 1 1 2 2 3 3 N N 2 X X
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